Scarica l'app Stockscreener
1.175
7.48%
0.105
Precedente Chiudi:
$1.07
Aprire:
$1.06
Volume 24 ore:
684.46K
Relative Volume:
0.33
Capitalizzazione di mercato:
$17.53M
Reddito:
-
Utile/perdita netta:
$-11.90M
Rapporto P/E:
-0.0057
EPS:
-206.0125
Flusso di cassa netto:
$-12.75M
1 W Prestazione:
+16.06%
1M Prestazione:
+10.58%
6M Prestazione:
-25.81%
1 anno Prestazione:
-16.67%
Intervallo 1D:
$1.0599
$1.17
Intervallo di 1 settimana:
$0.953
$1.19
Portata 52W:
$0.1131
$3.95
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Confronta ALLR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.165 | 17.53M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
506.33 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.17 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
631.43 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.70 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.88 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
The Psychology of Allarity Therapeutics Inc Inc. (ALLR) Price Performance: Understanding Market Sentiment - investchronicle.com
Upward Trajectory: Allarity Therapeutics Inc (ALLR) Posts a Slidee, Closing at 1.07 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Allarity unveils new multiple myeloma treatment predictor - Investing.com
Allarity unveils new multiple myeloma treatment predictor By Investing.com - Investing.com India
Healthy Upside Potential: Allarity Therapeutics Inc (ALLR) - Sete News
Allarity Therapeutics Presents Novel Drug Response - GlobeNewswire
Novel AI Predictor Identifies Multiple Myeloma Patients for Targeted Treatment | ALLR Stock News - Stock Titan
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
How to interpret Allarity Therapeutics Inc (ALLR)’s stock chart patterns - uspostnews.com
Allarity Therapeutics Inc (ALLR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Allarity Therapeutics Restructures Board of Directors - TipRanks
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
Allarity Therapeutics stock hits 52-week low at $0.67 - Investing.com
Allarity Therapeutics stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - Stocksregister
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Allarity Therapeutics, Inc. SEC 10-K Report - TradingView
Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan
Allarity Therapeutics Inc. (ALLR) reports earnings - qz.com
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter
Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World
Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia
Allarity Therapeutics probes potential stock manipulation - Investing.com
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan
Investigation announced for Long-Term Investors in shares - openPR.com
ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times
Allarity reports promising ovarian cancer trial results - Investing.com
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian
Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
Can you now get a good deal on Allarity Therapeutics Inc’s shares? - uspostnews.com
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com
Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia
SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire
Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):